RPC(SZ:000650)2021-04-27 16:00Financial Performance - The company's operating revenue for Q1 2021 was ¥1,182,488,435.13, representing a 34.08% increase compared to ¥881,907,797.30 in the same period last year[10] - Net profit attributable to shareholders for Q1 2021 was ¥150,038,498.65, up 45.38% from ¥103,207,337.83 in the previous year[10] - The net profit after deducting non-recurring gains and losses was ¥144,686,276.35, reflecting a 41.75% increase from ¥102,069,157.68 year-on-year[10] - Basic earnings per share for Q1 2021 were ¥0.1072, an increase of 28.69% compared to ¥0.0833 in the same period last year[10] - The company reported a 40.04% increase in operating costs to ¥711,391,937.76, correlating with revenue growth[25] - The company's tax expenses increased by 58.10% to ¥50,465,672.59, reflecting higher income tax due to increased revenue[25] - The total profit for the current period is 226,818,225.41, compared to 147,918,996.44 in the previous period, marking an increase of around 53%[88] - The basic earnings per share for the current period is 0.1072, compared to 0.0833 in the previous period, indicating an increase of approximately 28.5%[91] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,578,631,706.64, a 4.34% increase from ¥6,305,052,157.97 at the end of the previous year[10] - The total liabilities increased to ¥929,264,496.30 from ¥656,743,696.87, representing a rise of approximately 41.4%[81] - The total equity attributable to shareholders of the parent company rose to ¥3,649,264,463.42, compared to ¥3,651,953,197.62 in the previous period, indicating a slight decrease of about 0.1%[81] - The company's undistributed profits increased to ¥870,374,629.00 from ¥873,063,363.20, showing a marginal decline of approximately 0.2%[81] - The total current assets amount to CNY 3,741.83 million, a slight decrease from CNY 3,833.46 million at the end of the previous period[66] Cash Flow - The company reported a net cash flow from operating activities of -¥2,761,084.11, an improvement from -¥32,536,765.31 in the same period last year[10] - Cash inflow from operating activities totaled 997,147,631.80, a decrease from 1,324,703,540.70 in the previous period[103] - Cash outflow from investing activities was 2,730,085,628.03, compared to 2,192,402,116.55 in the previous period[103] - The net increase in cash and cash equivalents was -532,105,496.71, compared to an increase of 700,438,009.66 in the previous period[105] Investments - The company reported a loss of 193.70 million CNY from securities investments during the reporting period, with a total investment of 2.55 billion CNY[44] - The total fair value of securities held at the end of the reporting period was 843.09 million CNY[44] - The company has invested CNY 251,431.02 million in bank financial products, with an outstanding balance of CNY 40 million[56] Research and Development - Research and development expenses increased by 31.90% to ¥11,404,329.12, driven by significant investments in new drug development[25] - Research and development expenses increased to 11,404,329.12 from 8,646,264.75, reflecting a growth of approximately 32.3%[88] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 94,458, with the largest shareholder holding 23.24% of the shares[14] - The company is actively engaging with investors, having responded to 15 inquiries during the reporting period[61] Compliance and Governance - The company committed to ensuring independence in personnel, assets, business, finance, and organization after becoming a controlled subsidiary of Renhe Group[40] - The company has pledged to avoid any business competition with Renhe Group and its subsidiaries[40] - The company has committed to strict compliance with legal procedures for any related party transactions[40] Miscellaneous - The company received government subsidies amounting to ¥5,407,929.68 during the reporting period[10] - The first quarter report was not audited[112]